Abstract

Niemann-Pick type C2 (NP-C2) disease is a rare hereditary disease caused by mutations in the NPC2 gene. NPC2 is a small, soluble protein consisting of 151 amino acids, primarily expressed in late endosomes and lysosomes (LE/LY). Together with NPC1, a transmembrane protein found in these organelles, NPC2 accomplishes the exclusion of cholesterol; thus, both proteins are essential to maintain cellular cholesterol homeostasis. Consequently, mutations in the NPC2 or NPC1 gene result in pathophysiological accumulation of cholesterol and sphingolipids in LE/LY. The vast majority of Niemann-Pick type C disease patients, 95%, suffer from a mutation of NPC1, and only 5% display a mutation of NPC2. The biochemical phenotype of NP-C1 and NP-C2 appears to be indistinguishable, and both diseases share several commonalities in the clinical manifestation. Studies of the pathological mechanisms underlying NP-C2 are mostly based on NP-C2 animal models and NP-C2 patient-derived fibroblasts. Recently, we established induced pluripotent stem cells (iPSCs), derived from a donor carrying the NPC2 mutations c.58G>T/c.140G>T. Here, we present a profile of pathophysiological in vitro features, shared by NP-C1 and NP-C2, of neural differentiated cells obtained from the patient specific iPSCs. Profiling comprised a determination of the NPC2 protein level, detection of cholesterol accumulation by filipin staining, analysis of oxidative stress, and determination of autophagy. As expected, the NPC2-deficient cells displayed a significantly reduced amount of NPC2 protein, and, accordingly, we observed a significantly increased amount of cholesterol. Most notably, NPC2-deficient cells displayed only a slight increase of reactive oxygen species (ROS), suggesting that they do not suffer from oxidative stress and express catalase at a high level. As a site note, comparable NPC1-deficient cells suffer from a lack of catalase and display an increased level of ROS. In summary, this cell line provides a valuable tool to gain deeper understanding, not only of the pathogenic mechanism of NP-C2, but also of NP-C1.

Highlights

  • We developed neuronal cell models based on Niemann-Pick type C1 (NP-C1)-patient specific induced pluripotent stem cells (iPSCs) [7,8,9]

  • The protocol used for this purpose contains a pre-differentiation of iPSCs into neural progenitor cells (NPCs) and a final step for differentiation of Neural progenitor cells (NPCs) into neural differentiated cells (NDCs), namely neurons and glia cells

  • NPC2-deficient cells and control cells results in mixed cultures, containing neurons and glia cells, comparable to recently described NPC1-deficient cell model systems based on patient-specific iPSCs [7,10]

Read more

Summary

Introduction

The proteins NPC1 and NPC2 accomplish the exclusion of creativecommons.org/licenses/by/ 4.0/). Cholesterol from late endosomes and lysosomes and are essential for maintaining cellular cholesterol homeostasis [1]. Mutations in NPC1 or NPC2 result in pathophysiological accumulation of cholesterol and sphingolipids in lysosomes and late endosomes. Comparison of clinical and biochemical phenotypes in human patients disclosed no qualitative difference, proving that NPC1 and NPC2 proteins are essential for the transport of cholesterol in lysosomal compartments in a cooperative manner [2]. Clinical manifestation of Niemann-Pick type C1 (NP-C1) disease and Niemann-Pick type C2 (NP-C2) disease share several commonalities; about 95% of NP-C patients show mutations of the NPC1 gene and only 5% harbor mutations of the NPC2 gene [3]. The knowledge of the clinical presentation of NP-C1 is much more advances than the knowledge of NP-C2

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call